[Economic assessment of genetic test in breast cancer treatment]

Escalona-López S, Callejo-Velasco D, Blasco-Amaro JA, Guerra-Rodríguez M
Record ID 32015000006
Authors' recomendations: In this Oncotype DX economic model, we have evaluated two options, to prescribe chemotherapy for patients with RE> 30 values or for patients with RS>18. In the spanish setting, for a willingness to pay € 30,000 per QALY, the best option would appear to be to prescribe chemotherapy for patients with an Oncotype DX RS>18. This result is similar to Tsoi et al. results and different with regard to Hornberger et al. results. This model does not provide information relative to other test as MammaPrint, to compare results. There are needed more studies in this context between different commercialized tests. In relation with the studies assessed, there are suggested more studies that include indirect costs analysis as well as major number of studies with women N+, since the update results obtained are not conclusive.
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Breast Neoplasms
  • Genetic Testing
  • Cost-Benefit Analysis
Organisation Name: Unidad de Evaluacion de Tecnologias Sanitarias
Contact Address: Elena Andradas Aragones, Unidad de Evaluacion de Tecnologias Sanitarias, Agencia Lain Entralgo, C/ Gran Via, 27, 8a, ES-28013 Madrid, Spain. Tel: +34 91 3089418; Fax: +34 91 3089458;
Contact Name: elena.andradas@salud.madrid.org
Contact Email: elena.andradas@salud.madrid.org
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.